newsfilter
← Latest News
GlobeNewswire·

Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates

-- Patient Enrollment Completed in OraGrowtH210 and OraGrowtH212 Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected Q4 2023 -- -- Additional Data from OraGrowtH Trials to be Presented at